key: cord-1047063-zd9age7q authors: Iacobellis, Gianluca; Malavazos, Alexis Elias; Basilico, Sara; Tresoldi, Silvia; Rinaldo, Rocco Francesco; Dubini, Carola; Capitanio, Gloria; Serpi, Francesca; Schiaffino, Simone; Oliva, Omar Alessandro; Cariati, Maurizio; Morricone, Lelio; Centanni, Stefano; Sardanelli, Francesco; Carruba, Michele; Corsi Romanelli, Massimiliano Marco; Secchi, Francesco title: Epicardial fat inflammation response to COVID‐19 therapies date: 2021-05-24 journal: Obesity (Silver Spring) DOI: 10.1002/oby.23232 sha: 0d43e057ae5e2491f21d4d9ab030afc866a50e64 doc_id: 1047063 cord_uid: zd9age7q OBJECTIVE: Adipose tissue plays a role in the novel coronavirus disease 2019 (COVID‐19). Epicardial adipose tissue (EAT), a unique visceral fat, presents with high degree of inflammation in severe COVID‐19 disease. Whether and how adipose tissue may respond to the COVID‐19 therapies is unknown. METHODS: We retrospectively analyzed the difference in computed tomography (CT) measured EAT and subcutaneous (SAT) attenuation, defined as mean attenuation expressed in Hounsfield units (HU), in 72 patients [mean±SD age was 59.6±12.4 years, 50 (69%) were men] at the hospital admission for COVID‐19 and 99 days [IQR (71‐129)] after discharge. RESULTS: At the admission, EAT HU was significantly correlated with blood glucose levels, interleukin 6 , troponin T levels and waist circumference. EAT HU decreased from ‐87.21±16.18 to ‐100.0±11 (p<0.001) whereas SAT HU did not change (‐110.21±12.1 to ‐111.11±27.82, p=0.78) after therapy. Changes in EAT HU (expressed as ∆) significantly correlated with dexamethasone therapy (r= ‐ 0.46, p= 0.006), and when dexamethasone was combined with tocilizumab (r= ‐0.24, p=0.04). CONCLUSIONS: Dexamethasone therapy was associated with significant reduction of EAT inflammation in COVID‐19 patients, whereas SAT showed no changes. Anti‐inflammatory therapies targeting visceral fat may be helpful in COVID‐19 diseases. Obesity plays an important role in the coronavirus disease 2019 (COVID-19) [1] . Subjects with obesity, particularly those with predominant visceral adipose tissue (VAT) accumulation, are at higher risk of more serious COVID-19 complications [2] . Adipose tissue appears to serve as reservoir for the viral spread and inflammatory response amplification [3] . However, whether and how adipose tissue may respond to the COVID-19 therapies is unknown. We sought to evaluate the effects of various therapeutic COVID-19 protocols on epicardial adipose tissue (EAT). We focused our attention to this visceral fat depot for a number of reasons. EAT is a peculiar adipose tissue with highly inflammatory infiltrate, transcriptome and proteasome [4] [5] . Computed tomography-measured EAT attenuation is a novel marker of cardiovascular risk as it reflects inflammatory changes within the fat depot itself and is increased in patients with coronary artery disease [6] [7] . EAT has been suggested to play a role in COVID-19 cardiomyopathy [8] and we and others associated EAT density with COVID-19 severity [9] [10] [11] . Last, but not least EAT rapidly and significantly responds to drugs targeting the fat [12] . We therefore hypothesize that COVID-19 hospital therapies may change EAT density in patients who were admitted for COVID-19 disease. This article is protected by copyright. All rights reserved This was a retrospective, multicenter study. Patients' data were collected from the electronic medical records at the admission, during the hospitalization and after the discharge. Due to the retrospective nature of this analysis, informed consent was deemed as not necessary and waived, as approved by the local ethical committee (Ethics Committee of San Raffaele Clinical Research Hospital). Patient confidentiality was protected by assigning anonymous identification codes. We analyzed patients with confirmed diagnosis of COVID-19 who were admitted at the ASST Santi Paolo e Carlo Hospital (center 1) and IRCCS Policlinico San Donato (center 2) from March 3 to July 9, 2020. Four hundred twenty-seven patients met the following inclusion criteria: (1) diagnosis of COVID-19 confirmed with reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay of a specimen collected on a nasopharyngeal swab; (2) chest CT imaging suggestive for COVID-19 pneumonia; and (3) age > 18 years. COVID-19 disease severity was rated according to the latest WHO guidelines [13] . After discharge, patients were scheduled for a follow-up CT scan, as per hospital protocol. Patients who could not return for the follow-up CT or who had a poorquality image were excluded. Seventy-two patients were eventually included in the analysis. Chest CT images were retrospectively analyzed for EAT measurement, at hospital admission and at follow-up. Non-contrast images were evaluated. Scan protocol was optimized for lung evaluation, no electrocardiogram gating was used. Two expert radiologists (F.S. and S.T.) independently interpreted the images. First, each reader chose the axial slice which allowed the best visualization of EAT in the anterior interventricular sulcus at the mid-level of left anterior descending coronary artery. EAT and subcutaneous adipose tissue (SAT) attenuation was defined as mean attenuation expressed in Hounsfield units (HU). A region of interest (ROI) was placed in the EAT visualized in the anterior interventricular sulcus and in the anterior thorax SAT to obtain HU value, as previously This article is protected by copyright. All rights reserved described [9] . Coronary artery calcification (CAC) score was also calculated, as previously described [9] . The percentage of each lung zone involvement was scored using the following system: 0: no involvement, 1: <25%, 2: 26%-50%, 3: 51%-75% and 4: >75%. Total lung involvement score was calculated by summing scores of all of the three zones of the two lungs (maximum score = 24), as previously described [14] . During the hospitalization, patients received the following therapies, combined or in monotherapy: a) oral or intravenous (IV) dexamethasone 6 mg once daily for up to 10 days [15] ; b) hydroxychloroquine 200 mg 3 times daily for 7 to 10 days and azithromycin 500 mg once daily for 7-10 days [16] ; c) remdesevir 200 mg on day 1, followed by 100 mg once daily for the subsequent 5 or 10 days [17] ; d) lopinavir 200 mg or ritonavir 50 mg twice daily for 5-7 days [18] ; e) tocilizumab (8 mg/Kg, IV not exceeding 800 mg) [19] ; f) enoxaparin 4000 UI/ daily up to 14 days. Continuous variables are presented as means with their standard deviations (SDs) or medians for skewed data with interquartile range [IQR] or percentage (%). Differences in the study parameters were evaluated with multiple t-tests with 95% confidence intervals (C.I.). The difference in EAT-HU and other parameters before and after the hospital treatment was calculated as delta (∆). Relations between study variables were calculated using univariate regression analysis with Pearson or Spearman (rho) coefficient for skewed data with two-tailed p < 0.05 indicating statistical significance. Multivariate regression analyses were performed to evaluate which therapy most relevantly changed EAT attenuation and which laboratory value was independently related to EAT attenuation at baseline. Statistical analysis was performed using SPSS 26, Armonk, NY: IBM Corp. This article is protected by copyright. All rights reserved Baseline characteristics of patients are reported in Table 1 . At follow-up, 99 days [IQR (71-129)] after discharge, EAT-HU decreased from -87.21 ±16.18 to -100.0±11 (p<0.001) 95% CI from 9.89 to 15.83, whereas SAT-HU did not change (-110.21±12.1 to -111.11±27.82, p=0.78) after therapy (Figure 1) . CT-measured EAT thickness also reduced from 6.2±2.2 to 5.9±2.4 mm, p=0.03, 95% CI from 0.023 to 0.677 after therapy; as expected, c-reactiveprotein significanty decreased from 79.0±50.29 to 6.3±4.5 (p<0.001), 95 % CI from 60.61 to 84.72 between hospital admission and follow-up. Neither body mass index (BMI) or waist circumference significantly changed during the admission (from 28.1±5.4 to 27.5±4 kg/m 2 ; from 100.3±11 to 100±10 cm, respectively). At the admission, EAT-HU was strongly correlated with blood glucose levels (r= -0.70, p<0.01), interleukin 6 (r= -0.48, p<0.01), troponin T levels (r= -0.36, p<0.01), waist circumference (r= -0.37, p<0.01), age (r= -0.30, p<0.01) whereas there was no significant correlation with BMI, gender, preexisting conditions, or CAC score. We looked at the correlation between the different hospital therapeutic protocols and EAT-HU changes expressed as ∆, between the admission and follow-up. Thirty-three out of the 72 patients received dexamethasone, 11 patients received dexamethasone combined with tocilizumab, 21 patients used lopinavir or ritonavir, whereas 60 patients were treated with hydroxychloroquine. EAT-HU reduction was greater in those who received dexamethasone as compared to any of the other therapy (p<0.01) (Figure 2) . When data were analyzed in patients who received combined or multiple therapies, EAT HU reduction was substantially similar between the combined drugs and dexamethasone monotherapy. ∆EAT-HU significantly correlated with the dexamethasone therapy This article is protected by copyright. All rights reserved (r= -0.46, p= 0.006), and when dexamethasone was combined with tocilizumab (r= -0.24, p=0.04), with oxygen therapy (r= -0.23, p= 0.04), although the last two correlations were milder. No statistically significant correlations between the other treatments and ∆EAT-HU were observed. ∆ EAT-HU was also associated with lung involvement score at follow-up (r=-0.27, p=0.017) whereas there was no relation between ∆EAT-HU and days of the admission. Multivariate regression analysis confirmed that dexamethasone therapy was the best independent correlate of EAT attenuation change (beta coeffient -0.46, t-value -3.88, p<0.01). therapies in admitted patients. CT-measured EAT attenuation was significantly elevated at the admission and then dramatically reduced to substantially normal values after the discharge. On the contrary, we found no changes in the SAT inflammation with the various COVID-19 therapies. Among the different therapeutic protocols, we found that CT-EAT inflammation reduction was stronger in patients who received dexamethasone. We and other groups recently reported that EAT inflammation is related with COVID-19 severity [9] [10] [11] . In this study we showed that EAT not only is a marker of inflammation, but it can serve as therapeutic target to anti-inflammatory treatment and particularly to dexamethasone. The lack of changes within SAT reinforces the hypothesis that VAT is a more sensitive target in COVID-19, as previously suggested [2] . Adipose tissue is a well-known target of glucocorticoids. If long-term corticosteroids use undoubtedly increases adipogenesis, their effect on the adipocytes is more complex. It is likely that EAT density reduction is associated with the dexamethasone anti-inflammatory effects, certainly not related to the weight loss, as these COVID-19 patients did not lose any significant weight during the hospitalization. Interestingly, some studies suggest lipolytic and brown-fat like effect of acute glucocorticoids [20] and EAT displays brown-fat like properties, so steroid may speed up EAT metabolism and free fatty acids mobilization ultimately causing reduction in EAT This article is protected by copyright. All rights reserved inflammation. Although dexamethasone produced the greatest change in EAT HU, the antiinflammatory effect of the IL-6 inhibitor tocilizumab could contribute to reduce EAT attenuation. The correlation of EAT attenuation with hyperglycemia, IL-6, and troponin levels suggests its use as early imaging marker of COVID-19-related inflammation and myocardial damage. In conclusion, dexamethasone therapy was associated with significant reduction of EAT inflammation in COVID-19 patients, whereas SAT showed no changes. Anti-inflammatory therapies targeting the VAT may be helpful in COVID-19. This analysis has several limitations as many COVID-19 studies. The independent effect of dexamethasone or other therapies on EAT should be assessed with randomized clinical trials. Most of these patients received multiple therapies, so it is difficult to discriminate whether EAT changes were related to the combined effects or one drug was predominant. Patients had the follow up CT approximately 3 months after discharge. Albeit we cannot rule out the potential confounding effects of other factors, patients were certainly off any of the COVID-19 therapies after the discharge. This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved COVID-19 Rise in Younger Adults with Obesity: Visceral Adiposity Can Predict the Risk Targeting the Adipose Tissue in COVID-19 Is Adipose Tissue a Reservoir for Viral Spread, Immune Activation, and Cytokine Amplification in Coronavirus Disease Epicardial adipose tissue has a unique transcriptome modified in severe coronary artery disease Epicardial fat: From the biomolecular aspects to the Accepted Article This article is protected by copyright. All rights reserved clinical practice Is epicardial fat attenuation a novel marker of coronary inflammation? Cardiac computed tomography-derived epicardial fat volume and attenuation independently distinguish patients with and without myocardial infarction Does epicardial fat contribute to COVID-19 myocardial inflammation? Epicardial Fat Inflammation in severe COVID-19 Obesity as a Potential Predictor of Disease Severity in Young COVID-19 Patients: A Retrospective Study Epicardial adipose tissue is associated with extent of pneumonia and adverse outcomes in patients with COVID-19 Liraglutide causes large and rapid Epicardial Fat reduction WHO: Clinical Management of Covid-19-Interim Guidance Frequency and Distribution of Chest Radiographic Findings in Patients Positive for COVID-19 Dexamethasone in Hospitalized Patients with Covid-19 Accepted Article This article is protected by copyright. All rights reserved Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 GS-US-540-5773 Investigators. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 Tocilizumab in patients with severe COVID-19: a retrospective cohort study Glucocorticoids Acutely Increase Brown Adipose Tissue Activity in Humans, Revealing Species-Specific Differences in UCP-1 Regulation This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved